Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromuscular Blockade

Interventions

DRUG: Sugammadex 2 mg/kg
DRUG: Sugammadex 4 mg/kg
DRUG: Neostigmine + Glycopyrrolate
DRUG: Neostigmine + Atropine

Sponsor

Merck Sharp & Dohme LLC